ELSEVIER
SAUNDERS

SURGICAL
CLINICS OF
NORTH AMERICA

Surg Clin N Am 85 (2005) 1347–1380

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

Acetaminophen
for chronic pain, in surgical patients, 219
in perioperative pain management, 1246

Achalasia, **483–493**
clinical features of, 483–484
evaluation of, 484–486
endoscopic, 486
esophagography in, 484
manometry in, 484–485
pH monitoring in, 486
management of, 486–491
botulinum toxin in, 486–487
cardiomyotomy in, 488
dilation procedures in, 487–488
fundoplication in, 489–490
Heller myotomy in, 489
laparoscopic, 490–491
laparoscopic, 488–491
pharmacologic, 486

Acid-peptic disorders, **895–906**. *See also* Ulcer disease.
gastric mucosal barrier and, 896–898
Helicobacter pylori and, 897, 909, 911
antibiotics for, 903
proton pump inhibitors for, 903
management of, 898–903
anticholinergic agents in, 898–899
bismuth compounds, 902–903
histamine-2 receptor antagonists in, 899–900
prostaglandin analogs in, 902
proton pump inhibitors in, 900–901
sucralfate in, 901
nonsteroidal anti-inflammatory drugs and, 897–898
drug cessation for, 903–904
histamine-2 receptor antagonists for, 904
proton pump inhibitors for, 904
physiology of acid secretion in, 896–898
protection against, prostaglandins in, 898
Zollinger-Ellison syndrome, management of, 904–905

Acticoat with Silcryst Nanocrystals, to prevent surgical site infections, 1130

Acute-phase proteins, in immunology, 3–4

Acute promyelocytic leukemia, diffuse intravascular coagulation and, 1207

Adrenal insufficiency, in critical illness, 1158

α2 Adrenergic agonists, for neuropathic pain, in surgical patients, 233

Advance directives, in surgical palliative care, 276–277
legal issues in, 292–293

Advanced cancer, **237–255**
anorexia and cachexia in, 237–240
assessment of, 239–240
management of, 240
pathophysiology of, 238–239
quality-of-life instruments in, 239–240
constipation in, 248–250
assessment of, 249
etiology of, 249
management of, 249–250
pathophysiology of, 248–249
delirium in, 243–245
diagnosis of, 243
management of, 244–245
pathophysiology of, 243–244
dyspnea in, 240–242
assessment of, 241
management of, 241–242, 315
anxiolytics in, 242
bronchodilators in, 242
opioids in, 241–242
oxygen in, 242
steroids in, 242
pathophysiology of, 240–241
fatigue in, 247–248
assessment of, 247–248
etiology of, 247

0039-6109/05/$ - see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/S0039-6109(05)00159-3

Advanced (*continued*)
management of, 248
pathophysiology of, 247
nausea and vomiting in, 245–247
assessment of, 246
etiology of, 245–246
management of, 246–247
pathophysiology of, 245
resting energy expenditure in, 238

Airway adjuncts, in anesthesia. *See* Anesthesia.

Airway management, in obese patients, 1286

AJCC staging system, for esophageal cancer, 556–557

Allergic contact dermatitis, versus latex allergy, 1332

Allison, contributions of, to antireflux surgery, 931–932

American Society of Anesthesiology, physical status score, 1119

g-Aminobutyric acid agonists, for neuropathic pain, in surgical patients, 232

Amiodarone, to prevent postoperative atrial fibrillation and flutter, 1010–1011

Amputation, neuropathic pain after, 228

Anaphylaxis, latex-induced, versus latex allergy, 1332–1333

Anastomotic leaks, bariatric surgery and, 829, 855–856

Anastomotic strictures, laparoscopic gastric bypass and, 125

Anemia
duodenal switch procedure and, 830
perioperative. *See* Perioperative anemia.

Anesthesia, **1075–1089**
airway adjuncts in, 1080–1085
Combitube in, 1084–1085
laryngeal mask airway in, 1082–1083
and postoperative nausea and vomiting, 1232–1233
depth of, monitoring of, 1086–1087
general, 1078–1080
fast-tracking in, 1079
total intravenous, 1079–1080
in elderly, and perioperative care, 1262–1263
in minimally invasive esophagectomy, 635
in transhiatal esophagectomy, 595
local
for neuropathic pain, in surgical patients, 233
in perioperative pain management, 1250–1251
monitored anesthesia care in, 1077–1078
regional, 1075–1076
continuous infusions of, in balanced perioperative analgesia, 1253–1254
target-controlled infusion pumps in, 1086
transesophageal echocardiography in, 1087

Anorexia, in advanced cancer. *See* Advanced cancer.

Anterior vagal interruption, limited, for ulcer disease, 926

Antiarrhythmics, for neuropathic pain, in surgical patients, 233

Antibiotics
for acid-peptic disorders, due to *Helicobacter pylori*, 903
for surgical site infections, 1131
to prevent surgical site infections. *See* Surgical site infections.

Anticholinergic drugs, for acid-peptic disorders, 898–899

Anticoagulants, and postoperative hemorrhage, 1203–1305

Anticoagulated patients, operative management of, **1179–1189**
agents that alter coagulation, 1180–1185
aspirin and clopidogrel, 1180–1182
heparin, 1183–1185
warfarin, 1182–1183
atrial fibrillation and, 1185
coagulation system in, 1179–1180
mechanical heart valves and, 1185–1187
venous thromboembolism and, 1187

Anticonvulsants
for neuropathic pain, in surgical patients, 231–232
to prevent seizures, from brain metastases, 331

Antidepressants, for neuropathic pain, in surgical patients, 231

Anti-emetic drugs, for gastroparesis, 982

Antimetabolites, in organ transplantation, 1279–1280

Antiobesity surgery. *See* Bariatric surgery.

Antiplatelet agents, to prevent venous thromboembolism, 1167

Antireflux surgery
for achalasia, 489–491
for esophageal strictures, 447–448
for gastroesophageal reflux disease, **399–410, 931–947**
complications of, **525–538**
diarrhea, 533–534
dysphagia. *See* Dysphagia.
gas bloat, 532–533
persistent and recurrent reflux, 525–528
slipped or misplaced wrap, 527–528
wrap herniation, 526–527
diagnostic studies before, 938–939
barium esophagram, 939
DeMeester score, 939
esophageal manometry, 939
gastrointestinal endoscopy, 938–939
pH tests, 939
failure of, 941–943
redo surgery for, 943–944
historical aspects of, 931–934
Allison, 931–932
Belsey, 932
Hill, 932–933
Nissen, 931
Nissen modifications, 933–934
in laparoscopic repair, of paraesophageal hernias, 115
in patients with dysmotility, 407–408
in patients with normal motility, 404–406
laparoscopic, patient selection for, 937–938
laparoscopic Nissen fundoplication, 935–937
mesh repair of hiatal hernias, 940–941
Nissen, 400–402
partial versus total fundoplication, 935
patient selection for, 937–938
quality of life after, 458–461, 534
short esophagus and, 939–940
Collis gastroplasty for, 940
Toupet, 402–404
versus EndoCinch procedure, 953
versus Stretta procedure, 473–474
for paraesophageal hernias, 423–424

Antroduodenal manometry, to assess gastric function, 971

Antropyloric coordination, physiology of, 970

Anxiolytics, for dyspnea, in advanced cancer, 242

Appendectomy, laparoscopic, and surgical site infections, 1118

Arrhythmias
local anesthesia and, 1250
postoperative. *See* Postoperative arrhythmias.

Arterial blood gas measurements, in preoperative evaluation, 1069

Arterial blood supply, of stomach, 880–881

Arthritis, obesity and, 686–687

Aspirin, effects of, on coagulation system, 1180–1182, 1194–1195, 1203

Atenolol, to prevent postoperative ventricular tachycardias, 1111

Atrial fibrillation and flutter
and risk of venous thromboembolism, 1185
obesity and, 686
postoperative, 1108–1111

Atrial tachycardias, postoperative, 1107

Atrioventricular heart block, postoperative, 1107

Atrioventricular nodal reentrant tachycardias, postoperative, 1108

Atropine, for acid-peptic disorders, 898–899

Azathioprine, in organ transplantation, 1279

B

Baclofen, for neuropathic pain, in surgical patients, 232

Balanced perioperative analgesia. *See* Perioperative pain management.

Bard EndoCinch procedure, for gastroesophageal reflux disease. *See* Endoscopic surgery.

Bariatric surgery. *See also specific procedures.*
age limits in, 729–730

Bariatric (*continued*)
choice of procedure in, 731–733
complications of, **853–868**
anastomotic leaks, 829, 855–856
bowel obstruction, 862
deep venous thrombosis, 858, 866
drainage problems, 856
factors influencing, 728
fascial dehiscence, 860–861
gallbladder disease, 863
inadequate weight loss, 858–860
incisional hernias, 861
jejunoileal bypass and, 864–865
laparoscopic banding procedures and, 865
laparoscopic gastric bypass and, 865–866
marginal ulceration, 861–862
nutritional deficiencies, 860
portal vein injury, 863–864
prevention of, 854–855
pulmonary embolism, 856–858, 866
respiratory disorders, 862–863
staple line disruption, 862
wound infections, 861
dietary management after, 713, 715–716
nutritional concerns in, 713, 715–716
protein malnutrition in, 715
refeeding syndrome in, 715–716
Wernicke-Korsakoff syndrome in, 716
dietary management before, 711–713
indications for, 726–730
insurance coverage for, **665–680**, 812–814
employer's role in, 669
evidence-based reviews of, 670–676
Blue Cross Blue Shield reviews, 674–675
Cochrane Review, 670, 672–674
RAND/Agency for Health Care Research and Quality review, 676
exclusion of, 669
historical aspects of, 665–667
restriction of, 667–669
under Medicare, 669–670
lack of access to, 758
patient information before, 729
patient selection for, 725–733
and outcomes, 730–731
body mass index in, 728–730
cultural differences in, 732
eating behaviors in, 732–733
gastroesophageal reflux disease in, 733
motivational factors in, 727
weight goals in, 731
perioperative care in, 1285
physiology of, 733–735
fatty acid secretion in, 735
gastric distention in, 733
gastrointestinal polypeptide patterns in, 735
ghrelin in, 734
glucagon-like peptide-1 in, 734–735
peptide YY in, 734–735
vagal signals in, 733–734
psychologic issues in, **741–755**
as predictors of weight loss, 748
assessment tests for, 745–748
eating disorders, 743
eating patterns, 743–744
existing challenges, 748–751
biochemical mechanisms of weight loss, 749–750
difficulties generating research, 751
genetic control, 749
presurgical psychopathology, 751
importance of, 741–742
prejudice and discrimination, 744
psychiatric disorders, 742–743
quality of life, 745
role of psychiatrists and psychologists, 751–752
socioeconomic class, 744
quality assurance in, **757–771**
advance quality planning in, 761–762
American Society for Bariatric Surgery Centers of Excellence in, 759
application for full approval in, 769
application process for, 766
program status in, 769–770
provisional status in, 766–769
requirements for, 765
assessment of best practices in, 759
Bariatric Surgery Review Committee in, 765
Board of Governors in, 764
definition of quality in, 760–761
industrial principles in, 762–763
literature review on, 759
quality assurance managers in, 762
quality improvement in, 760

research initiatives in, 760
significance of, 770–771
Surgical Review Corporation in, 763–764
urgency of, 763
weight loss after, and increased risk of mortality, 731

Barium contrast studies
of dysphagia, after fundoplication, 531
of epiphrenic diverticula, 499
of paraesophageal hernias, 419, 426–427
to stage esophageal cancer, 559

Barium esophagram, before antireflux surgery, 939

Barrett's esophagus
and esophageal cancer, 540–541
esophagectomy for. *See* Esophagectomy.

Belsey, contributions of, to antireflux surgery, 932

Benzodiazepines, for neuropathic pain, in surgical patients, 232

Beta-blockade, perioperative. *See* Perioperative beta-blockade.

Beta-blockers
to prevent postoperative atrial fibrillation and flutter, 1010–1011
to prevent postoperative ventricular tachycardias, 1111

Bile gastritis, Billroth procedures and, 921

Biliary cancer. *See* Pancreatic/biliary cancer.

Biliopancreatic diversion
for obesity, 836–840
and improvement in comorbidities, 840
complications of, 837–839
physiology of, 735
techniques for, 836–837
weight loss after, 839–840
inadequate, 860
with duodenal switch procedure, 735, 837–840, 864–865
with long-limb Roux-en-Y gastric bypass, 814–815
laparoscopic, for refractory morbid obesity. *See* Refractory morbid obesity.

Billroth procedures, for ulcer disease, 917, 919, 921
and bile gastritis, 921

Binge eating disorder, and patient selection, for bariatric surgery, 732–733, 743

Biologic agents, in organ transplantation, 1280

Bismuth compounds, for acid-peptic disorders, 902–903

Bispectral index, to monitor depth of anesthesia, 1086–1087

Bisphosphonates, for impending pathologic fractures, 350

Bleeding, postoperative. *See* Postoperative hemorrhage.

Bleeding time, tests of, for postoperative hemorrhage, 194–1195

Bleomycin, and perioperative care, in cancer patients, 1269

Blood products, and diffuse intravascular coagulation, 1207

Blood sugar, uncontrolled, and surgical site infections, 1128–1129

Blood supply, arterial, of stomach, 880–881

Blood transfusions
and postoperative hemorrhage, 1209–1210
and surgical site infections, 1127–1128
for perioperative anemia, 1223–1224

Blue Cross Blue Shield reviews, of bariatric surgery, 674–675

Boerhaave's syndrome, **515–524**
clinical features of, 516
diagnosis of, 517
management of, 517–523
defect exposure in, 520–521
drainage procedures in, 519
exclusion/diversion procedures in, 519–520
feeding jejunostomy in, 521–522
non-surgical, 518
results of, 522–523
segmental resection in, 521
pathophysiology of, 516–517

Bone marrow suppression, chemotherapy and, 1271

Botulinum toxin
for achalasia, 486–487
for gastroparesis, 983

Bowel obstruction
bariatric surgery and, 862
laparoscopic gastric bypass and, 123, 125

Bowel obstruction (*continued*)
laparoscopic rectal surgery and, 65–66

Brachytherapy, for esophageal cancer, 573–574

Bradycardias, postoperative. *See* Postoperative arrhythmias.

Brain metastases, **329–345**
clinical features of, 392–393
epidemiology of, 392–393
management of
for multiple or recurrent metastases, 336–337
from breast cancer, 339
from colorectal cancer, 339
from lung cancer, 338–339
from melanoma, 339–340
from prostate cancer, 340
from renal cell carcinoma, 339
medical, 393–394
radiation therapy in, 331–334
radiosurgery and other highly focused radiation, 332–334
versus surgery, 337–338
whole-brain fractionated external-beam, 331–332, 334, 336
surgical resection in, 334-336

Braun enteroenterostomy, for ulcer disease, 921

Breast cancer
brain metastases from, management of, 339
obesity and, 687–689

Bronchodilators, for dyspnea, in advanced cancer, 242

Buess technique, for transgastric resection, of early gastric cancer, 995

Bulimia nervosa, and patient selection, for bariatric surgery, 743

Bulking techniques, for gastroesophageal reflux disease, 474–477

Bupropion, for obesity, 711

Burn patients, venous thromboembolism in, prevention of, 1173

C

Cachexia, in advanced cancer. *See* Advanced cancer.

Calcineurin inhibitors, in organ transplantation, 1276–1278

Calcium, in energy metabolism and weight regulation, 707

Calcium oxalate kidney stones, jejunoileal bypass and, 864

Cancer
advanced. *See* Advanced cancer.
obesity and. *See* Obesity, health ramifications of.

Cancer patients
perioperative care in, 1267–1273
chemotherapy and, 1268–1273
cardiotoxicity of, 1268–1269
cutaneous toxicity of, 1272–1273
genitourinary toxicity of, 1270
hepatotoxicity of, 1269
myelosuppression by, 1271–1272
neurotoxicity of, 1270–1271
pulmonary toxicity of, 1269
venous thromboembolism in, prevention of, 1171–1172

Capsaicin, for neuropathic pain, in surgical patients, 234

Carbamazepine, for neuropathic pain, in surgical patients, 232

Carcinoid, gastric, limited resection of, 1017

Cardiac complications, of local anesthesia, 1250

Cardiac disease
in elderly, and perioperative care, 1260
in obese patients, and perioperative care, 1284

Cardiac evaluation, preoperative. *See* Preoperative evaluation.

Cardiomyotomy, for achalasia, 488

Cardiotoxicity, of chemotherapy, 1268–1269

Cardiovascular disease, obesity and, 685–686

Catheter-related infections. *See* Health care–associated infections.

Catheters, indwelling, for pleural effusions, 320, 321–322

Celiac plexus block, for cancer-related pain, 367

Cell-mediated immunity, in immunology, 4–7

Cementoplasty, for skeletal metastatic disease, 353

Central nervous system complications, of local anesthesia, 1250–1251

Cervical esophagogastric anastomosis, in transhiatal esophagectomy, 597–598

Chemical pleurodesis, for pleural effusions, 322–323

Chemical splanchnicectomy, for cancer-related pain, 366–367

Chemoradiotherapy
adjuvant, for gastric cancer, 1039–1042
for esophageal cancer, 623–624
neoadjuvant, for gastric cancer, 1046–1047

Chemotherapy
adjuvant
for gastric cancer, 1035, 1037
intraperitoneal, for gastric cancer, 1038–1039
and perioperative care, in cancer patients, 1268–1273
for brain metastases, 331
for esophageal cancer, 623
preoperative, 625–626
for gastric non-Hodgkin's lymphoma, 1014
neoadjuvant, for gastric cancer, 1042–1043, 1045

Cholecystectomy
immunology in, 5–7
laparoscopic, venous thromboembolism after, prevention of, 1170–1171

Choledochojejunostomy, for obstructive jaundice, 363

Chronic pain management, in surgical patients, 195–196, 197, 198, **209–224**
barriers to, 210–211
best practice in, 221–223
definition of chronic pain, 210
in surgical intensive care unit, 310
Internet resources for, 222
legal issues in. *See* Legal issues.
neuropathic pain, **225–236**
α-2 adrenergic agonists in, 233
after amputation, 228
after axillary lymph node dissection, 228
after mastectomy, 228
after radical neck dissection, 228
after thoracotomy, 228
g-aminobutyric acid agonists in, 232
antiarrhythmics in, 233
anticonvulsants in, 231–232
antidepressants in, 231
central mechanisms of, 226–227
definition of, 225–226, 227
equianalgesic dosing in, 230
methadone in, 230–231
N-methyl-D-aspartate receptor antagonists in, 233–234
opioids in, 229–231
peripheral mechanisms of, 226
steroids in, 232
symptoms of, 226
topical agents in, 234
nonpharmacologic, 214–216
pain assessment in, 212–214
pain mechanism and quality in, 214
pain physiology and, 212
pharmacologic, 216–221
acetaminophen in, 219
adjuvant analgesics in, 219–220
nonopioid analgesics in, 217–220
nonsteroidal anti-inflammatory drugs in, 217–219
opioids in, 220–221
tramadol in, 219
versus acute pain, 212–213
with end-stage organ failure, 376–377
with pancreatic/biliary cancer, 366–367

Chylothorax, transhiatal esophagectomy and, 603

Cimetidine, for acid-peptic disorders, 899–900

Cirrhosis, cryptogenic, jejunoileal bypass and, 864

Cisplatin
adjuvant, for gastric cancer, 1039
neoadjuvant, for gastric cancer, 1043, 1045
with radiation therapy, 1047

Clonazepam, for neuropathic pain, in surgical patients, 232

Clonidine, for neuropathic pain, in surgical patients, 233

Clopidogrel, effects of, on coagulation system, 1180–1182

Coagulation studies, for postoperative hemorrhage, 1194, 1198–1199

Cochrane Review, of bariatric surgery, 670, 672–674

Codeine, in perioperative pain management, 1249

Cognitive dysfunction, postoperative, in elderly, 1263–1264

Collis gastroplasty
for paraesophageal hernias, 427–428
for short esophagus, 439, 441, 444, 940
in laparoscopic repair, of paraesophageal hernias, 112

Collis-Nissen procedure, for short esophagus, 439, 441, 940

Colon cancer
and perioperative anemia, 1216–1217
brain metastases from, management of, 339
laparoscopic surgery for, **49–60**
advantages of, 51–54
excision and lymph node harvest, 54
gastrointestinal motility, 51–52
quality of life, 52–53
shortened hospital stay, 53–54
clinical evidence for, 51
hand-assisted, 50
immunology in, 3–6
long-term outcomes of, 54–56
technique for, 50
obesity and, 692

Colon interpositions, in esophageal reconstruction. *See* Esophageal reconstruction.

Colon surgery
and surgical site infections, 1122
venous thromboembolism after, prevention of, 1172

Combitube, in anesthesia, 1084–1085

Complete blood count, for postoperative hemorrhage, 1194, 1198–1199

Compression stocking, to prevent venous thromboembolism, 1170

Computed tomography, to stage esophageal cancer, 559–561

Conscious sedation, indications for, 1077–1078

Constipation, in advanced cancer. *See* Advanced cancer.

Contact dermatitis, versus latex allergy, 1331–1332

Continuous epidural catheters, in perioperative pain management, 1252–1253

Continuous hyperthermic peritoneal infusion, of chemotherapy, for gastric cancer, 1038–1039

Continuous positive airway pressure, for respiratory complications, of bariatric surgery, 863

Coronary heart disease, obesity and, 686

Correct-site surgery. *See* Patient safety practices.

Cortisol production, in organ transplantation, 1276

COX-2 inhibitors, in perioperative pain management, 1247

Cramping, transhiatal esophagectomy and, 605

C-reactive protein, in immunology, 3

Cricopharyngeal myotomy, with diverticulectomy, for pharyngoesophageal diverticula, 496, 498

Crohn's disease, laparoscopic surgery for, **25–34**
advantages of, 32
contraindications to, 27
diagnostic, 29
diversion techniques in, 29
hand-assisted, 29–30
indications for, 26–27
literature review on, 25–26
long-term outcomes of, 32
mesenteric division in, 30
outcome measures in, 26
resectional, 29–30
versus laparoscopic surgery for ulcerative colitis, 39–41

Cryptogenic cirrhosis, jejunoileal bypass and, 864

Cutaneous toxicity, of chemotherapy, 1272–1273

Cyclosporine, in organ transplantation, 1276–1278

Cystitis, hemorrhagic, chemotherapy and, 1270

Cytokines, in immunology, 3–6

D

Deep venous thrombosis. *See* Venous thromboembolism.

Delirium
in advanced cancer. *See* Advanced cancer.
postoperative, in elderly, 1263–1264

DeMeester score, before antireflux surgery, 939

Desflurane, in general anesthesia, 1079

Dexamethasone
for adrenal insufficiency, in septic shock, 1158
for neuropathic pain, in surgical patients, 232

Dexmedetomidine, in general anesthesia, 1080

Dextromethorphan, for neuropathic pain, in surgical patients, 234

Diabetes mellitus
elimination of, laparoscopic adjustable gastric band surgery and, 135–136
improvement in
laparoscopic adjustable gastric banding and, 801–802
Roux-en-Y gastric bypass and, 845–846
in obese patients, and perioperative care, 1285
in surgical patients, 1153–1156
diagnosis and classification of, 1154–1155
insulin-dependent, 1155
perioperative control of, 1155–1156
obesity and, 684–685
in children and adolescents, 685
uncontrolled, preoperative evaluation of, 1071

Diarrhea
fundoplication and, 533–534
transhiatal esophagectomy and, 605

Dietary therapy, for gastroparesis, 980

Diffuse intravascular coagulation, and postoperative hemorrhage. *See* Postoperative hemorrhage.

Digestion, gastric, physiology of, 887–888

Dilation procedures
for achalasia, 487–488
for esophageal strictures, 446–447

Direct thrombin inhibitors, in anticoagulated patients, 1184–1185

Diverticula, esophageal. *See* Esophageal diverticula.

Diverticular disease, laparoscopic sigmoid colectomy for, **19–24**
literature review on, 21–22
perioperative care for, 20–21
technique for, 19–20

Diverticulectomy
with cricopharyngeal myotomy, for pharyngoesophageal diverticula, 496, 498
with esophagomyotomy, for epiphrenic diverticula, 501–502

Domperidone, for gastroparesis, 981

Dor fundoplication, for achalasia, 489–490

Double gloving, to prevent sharps injuries, 1301

Doxorubicin
adjuvant, for gastric cancer, with radiation therapy, 1040
and perioperative care, in cancer patients, 1268–1269
neoadjuvant, for gastric cancer, 1043

Drainage problems, bariatric surgery and, 856

Drainage procedures, for Boerhaave's syndrome, 519

Duodenal obstruction, palliative care for. *See* Pancreatic/biliary cancer.

Duodenal switch procedure, **819–833**. *See also* Bariatric surgery.
complications of, 829–830
historical aspects of, 820–821
postoperative care for, 822
results of, 822–829, 831
demographics of, 823
morbidity and mortality, 827–829
nutritional and metabolic parameters, dietary volume, and bowel function, 825–827
quality of life, 831
revisional surgery, 829
weight loss, 823–825, 831
technique for, 821–822
with biliopancreatic diversion, 735, 837–840, 864–865

Duodenal ulcers, bleeding, surgical management of, 909–911

Dysphagia
esophageal strictures and, 445–446
fundoplication and, 528–532
diagnosis of, 531
gastric vessel division and, 529–530
patient factors in, 530–531
preoperative dysphagia and, 530
reoperation for, 531–532
surgical technique and, 529

Dyspnea, in advanced cancer. *See* Advanced cancer.

E

Eating Disorder Inventory, before and after bariatric surgery, 747

Eating disorders, and patient selection, for bariatric surgery, 732–733, 743

Eating patterns, and patient selection, for bariatric surgery, 743–744

Echocardiography, transesophageal, to monitor hemodynamically unstable patients, 1087

Eicosapentaenoic acid, for cachexia, in advanced cancer, 240

Electrogastrography, to assess gastric function, 971

Emptying, gastric, physiology of, 969–970

En-bloc esophagectomy, for esophageal cancer, **611–619**
cervical node metastases and, 616–617
failure of, 612
hospital mortality and morbidity in, 615–616
postoperative care for, 615
three-field procedure, 614–615
two-field procedure, 613–614

En-bloc lymphadenectomy, for esophageal cancer, 622

Endoluminal gastric surgery, **989–1007**
techniques for, 990–993
transgastric pancreatic pseudocyst drainage, 1000–1005
transgastric resection of early gastric cancer, 993–996
modified Buess technique for, 995–996
transgastric resection of gastrointestinal stromal tumors, 996, 998–1000
tools for, 991

Endoluminal stents, for gastric cancer, 1012

Endoscopic evaluation
of achalasia, 485
of epiphrenic diverticula, 500
of esophageal strictures, 446
of paraesophageal hernias, 419–420
of short esophagus, 436, 438

Endoscopic Plication System, for gastroesophageal reflux disease, 470

Endoscopic surgery
for esophageal cancer, 633
for gastroesophageal reflux disease, **465–481, 949–965**
Bard EndoCinch procedure in, 466–471, 951–953
clinical data on, 468–471, 952–953
preclinical data on, 951–952
technique for, 467–468, 951
versus laparoscopic Nissen fundoplication, 953
bulking procedures in, 474–477
Endoscopic Plication System in, 470
Enteryx injections in, 474–476, 959–960
clinical data on, 960
mechanism of action of, 474–475
preclinical data on, 959–960
results of, 475–476
technique for, 959
Gatekeeper system in, 477, 961–962
clinical data on, 961–962
preclinical data on, 961
technique for, 961
NDO Plicator in, 954–955
clinical data on, 954–955
preclinical data on, 954
technique for, 954
polymethylmethacrylates in, 476–477
mechanism of action of, 476
results of, 477
rationale for, 466
Stretta procedure in, 471–474, 956–958
clinical data on, 957–958
mechanism of action of, 471–472
preclinical data on, 956–957
results of, 472–474
technique for, 472, 956
Wilson-Cook suturing device in, 470–471

Endoscopic ultrasonography
to stage esophageal cancer, 556, 561–562
with fine-needle aspiration, to stage esophageal cancer, 556, 562

Endoscopy
gastrointestinal, before antireflux surgery, 938–939
to assess gastric function, 970

Endotracheal intubation, and pneumonia, 1139

Energy output, increased, for obesity, 707–709

Enoxaparin, to prevent venous thromboembolism, 1172

Enteroenterostomy, Braun, for ulcer disease, 921

Enteryx injections, for gastroesophageal reflux disease. *See* Endoscopic surgery.

Epidural anesthesia, indications for, 1075–1076

Epidural catheters, continuous, in perioperative pain management, 1252–1253

Epiphrenic diverticula. *See* Esophageal diverticula.

Epirubicin
adjuvant, for gastric cancer, 1037
neoadjuvant, for gastric cancer, 1045

Erythromycin, for gastroparesis, 981

Esomeprazole, for acid-peptic disorders, 900–901, 903, 904

Esophageal cancer
en-bloc esophagectomy for. *See* En-bloc esophagectomy.
epidemiology of, 539–541
Barrett's esophagus in, 540–541
Ivor Lewis esophagogastrectomy for. *See* Ivor Lewis esophagogastrectomy.
minimally invasive esophagectomy for. *See* Minimally invasive esophagectomy.
molecular biology of, **539–553**, 564–565
future directions in, 548
genomics in, 547–548
gene microarrays, 547–548
reverse transcriptase-polymerase chain reaction assay in, 564–565
tumor cell biology in, 541–547
autonomous growth, 543, 545
aversion to apoptosis, 546
cell cycle, 541
ignoring antiproliferative signals, 545
invasion and metastasis, 546–547
promoting neo-angiogenesis, 546
tumorigenesis, 542–543
unlimited replication, 546
multimodality management of, **621–630**
chemoradiation in, 623–624
chemotherapy in, 623
preoperative, 625–626
esophagectomy in, 621–622
pretreatment staging and, 627–628
radiation therapy in, 622–623
postoperative, 624–625
preoperative, 625–626
trimodality therapy in, 626–627
palliation of, **569–581**
brachytherapy in, 573–574
expandable metal stents in, 574–575
advantages of, 578–579
complications of, 575–578
versus plastic stents, 578
versus thermal ablation therapy, 579
Nd:YAG laser therapy in, 572
photodynamic therapy in, 569–573
complications of, 571–572
Photofrin in, 572
staging of, **555–567**
AJCC system in, 558
and outcome, 555, 622
barium contrast studies in, 559
computed tomography in, 559–561
endoscopic ultrasonography in, 556, 561–562
with fine-needle aspiration, 556, 562
magnetic resonance imaging in, 560–561
positron emission tomography in, 556, 560–561
surgical, 562–564
laparoscopic, 563, 564
thoracoscopic, 563, 564
TNM system in, 556–557

Esophageal dilation, laparoscopic
adjustable gastric band surgery and, 133

Esophageal diverticula, **495–503**
epiphrenic, 499–502
clinical features of, 499
diagnosis of, 499–500
management of, 501–502
pharyngoesophageal (Zenker's), 495–499
clinical features of, 495–496
diagnosis of, 496
management of, 496, 498–499
diverticulectomy with cricopharyngeal myotomy in, 496, 498
traction, 502

Esophageal function tests, for
paraesophageal hernias, 420

Esophageal lengthening procedures
for paraesophageal hernias, 426–428
for short esophagus, 441, 444

Esophageal manometry, before antireflux surgery, 939

Esophageal reconstruction, **505–514**
choice of graft in, 507
colon interpositions in, 508–511
alternate grafts in, 512
anatomy aberrancies and, 511–512
jejunal interpositions in, 512–514
preoperative evaluation for, 507–508
surgical planning for, 506–507

Esophageal strictures, 445–448
diagnosis of, 445–446
management of, 446–448
dilation in, 446–447
esophagectomy in, 448
fundoplication in, 447–448
laparoscopic, 447
pathogenesis of, 445

Esophagectomy
for Barrett's esophagus, 654–655
functional results of, 654
quality of life after, 654–655
for Boerhaave's syndrome, 521
for esophageal cancer, 621–622
clinical findings on, 650–651
en-bloc. *See* En-bloc esophagectomy.
functional results of, 651
minimally invasive. *See* Minimally invasive esophagectomy.
quality of life after, 651–653
transhiatal. *See* Transhiatal esophagectomy.
transthoracic, for esophageal cancer, 632
for esophageal strictures, 448

Esophagogastrectomy, Ivor Lewis. *See* Ivor Lewis esophagogastrectomy.

Esophagography
of achalasia, 484
of esophageal strictures, 446
of short esophagus, 435–436

Esophagomyotomy, with diverticulectomy, for epiphrenic diverticula, 501–502

Esophagram, barium, before antireflux surgery, 939

Esophagus
postemetic rupture of. *See* Boerhaave's syndrome.
short. *See* Short esophagus.

Ethical issues, in surgical palliative care, **273–286**
autonomous decision-making, 275–277
advance directives in, 276–277, 292–293
definition of autonomy, 275–276
character as moral guide, 274–275
euthanasia and physician-assisted suicide, 281–285
futile care, 279–281, 380
ordinary and extraordinary treatments, 278–279
principles of moral reasoning, 274
refusal of treatment, 379–380
terminal sedation and principle of double effect, 281, 282, 288
withholding and withdrawing treatment, 278

Etoposide, neoadjuvant, for gastric cancer, 1043

Eutectic mixture of local anesthetics, for neuropathic pain, in surgical patients, 234

Euthanasia, in surgical palliative care, 281–285

Exclusion/diversion procedures, for Boerhaave's syndrome, 519–520

Exercise, for gastroparesis, 980

Expandable metal stents
for esophageal cancer. *See* Esophageal cancer.
for tracheoesophageal fistulas, 579

F

Famotidine, for acid-peptic disorders, 899–900

Fascial dehiscence, bariatric surgery and, 860–861

Fast-tracking
in general anesthesia, 1079
in perioperative care, 1325

Fatigue, in advanced cancer. *See* Advanced cancer.

Fatty acid secretion, in bariatric surgery, 735

Feeding jejunostomy, for Boerhaave's syndrome, 521–522

Fentanyl, in perioperative pain management, 1249

Fine-needle aspiration, with endoscopic ultrasonography, to stage esophageal cancer, 556, 562

5-Fluorouracil
adjuvant, for gastric cancer, 1037, 1038
with radiation therapy, 1039–1042
neoadjuvant, for gastric cancer, 1043, 1045
with radiation therapy, 1046–1047

Folinic acid
adjuvant, for gastric cancer, 1037
neoadjuvant, for gastric cancer, 1043
with radiation therapy, 1047

Foregut continuity, restoration of, for ulcer disease, 917, 919, 921–924

Fractures, impending pathologic, management of, 349–352

Fresh-frozen plasma, for postoperative hemorrhage, 1204–1205

Futile care, in surgical palliative care, 279–281, 380

G

Gabapentin, for neuropathic pain, in surgical patients, 231–232

Gallbladder disease, bariatric surgery and, 863

Gas bloat, fundoplication and, 532–533

Gastrectomy
laparoscopic, for gastric tumors. *See* Gastric tumors.
partial, for ulcer disease, 917, 919, 921–924
proximal subtotal, for proximal gastric cancer, 1011

Gastric acid, secretion of, neuroendocrine regulation of, 884–886

Gastric bypass surgery
conversion to, from laparoscopic adjustable gastric banding, 779
laparoscopic
complications of, 865–866
for refractory morbid obesity. *See* Refractory morbid obesity.
physiology of, 734
Roux-en-Y. *See* Roux-en-Y gastric bypass.

Gastric cancer
adjuvant therapy for, 1035–1042
chemoradiotherapy in, 1039–1042
chemotherapy in, 1035, 1037
intraperitoneal therapy in, 1038–1039
clinical features of, 1033–1035
diagnosis of, 1023
sentinel lymph node biopsy in, 1023
early, transgastric resection of, 993–996
Lauren classification of, 1021–1022
limited resection of, **1009–1020**
extent of, 1009–1010
gastric carcinoid, 1017
gastrointestinal stromal tumors, 1014–1017
non-Hodgkin's lymphoma, 1012–1014
palliative, 1011–1012
proximal cancer, 1010–1011
neoadjuvant therapy for, 1042–1047
preoperative chemoradiotherapy in, 1046–1047
preoperative chemotherapy in, 1042–1043, 1045
preoperative radiotherapy in, 1045–1046
pattern of spread of, 1034–1035
radical gastrectomy for, **1021–1032**
lymph node dissection in, 1025–1029
preoperative preparation for, 1029–1030
tumor location and, 1030
risk factors for, 1022
staging of, 1024

Gastric cancer (*continued*)
TNM system in, 1024

Gastric cancer, and perioperative anemia, 1216

Gastric carcinoid, limited resection of, 1017

Gastric digestion, physiology of, 887–888

Gastric function
assessment of, 970–972
in response to meal, 889–891

Gastric hernias, laparoscopic adjustable gastric band surgery and, 132

Gastric motility
normal myoelectrical activity in, 972–973, 975
pacemaker region/activity in, 972
physiology of, 888–889, 972–975

Gastric mucosa
alkaline secretion by, 886–887
functional anatomy and physiology of, 884

Gastric pacing, for gastroparesis, 983–984

Gastric stimulation, for gastroparesis, 983–984

Gastric surgery, endoluminal. *See* Endoluminal gastric surgery.

Gastric tumors, laparoscopic surgery for, **151–164**
gastrectomy, 156–160
histologic findings in, 159
indications for, 156
operative findings in, 159
outcomes of, 157, 159
postoperative care for, 159–160
techniques for, 156–157
gastric gastrointestinal submucosal tumors, 161
historical aspects of, 151–152
local resection
indications for, 152–154
intragastric mucosal resection, 154
outcomes of, 155–156
techniques for, 154–156
wedge resection, 154

Gastritis, bile, Billroth procedures and, 921

Gastroduodenotomy, transpyloric, for bleeding duodenal ulcers, 910

Gastroesophageal junction, anatomy of, 876

Gastroesophageal reflux disease
and esophageal strictures. *See* Esophageal strictures.
and patient selection, for bariatric surgery, 733
and short esophagus. *See* Short esophagus.
antireflux surgery for. *See* Antireflux surgery.
endoscopic surgery for. *See* Endoscopic surgery.
etiology of, 399
fundoplication for. *See* Antireflux surgery.
improvement in, laparoscopic adjustable gastric banding and, 802
quality of life instruments in, **452–463**
after medical management, 457–458, 460–461
after surgical management, 458–461, 534
characteristics of, 454–455
disease-specific, 456–457
Gastroesophageal Reflux Disease Activity Index, 460
Gastroesophageal Reflux Disease-Health Related Quality of Life Scale, 456–457, 459, 461
Gastrointestinal Symptom Rating Scale, 456–458, 461
generic, 455–456
in untreated disease, 457
Karnofsky index, 453
Medical Outcomes Short Form 36, 455–461
Psychological General Well-Being Index, 456–458, 461
Reflux-Related Visual Analogue Scale, 456–457
symptoms of, with paraesophageal hernias, 416–417, 423

Gastroesophageal Reflux Disease Activity index, of quality of life, in gastroesophageal reflux disease, 460

Gastroesophageal Reflux Disease-Health Related Quality of Life Scale, in gastroesophageal reflux disease, 456–457, 459, 461

Gastrointestinal endoscopy, before antireflux surgery, 938–939

Gastrointestinal motility, after laparoscopic surgery, for colon cancer, 51–52

Gastrointestinal polypeptide patterns, in bariatric surgery, 735

Gastrointestinal stromal tumors
imatinib mesylate for, 1016–1017
limited resection of, 1014–1017
transgastric resection of, 996, 998–1000

Gastrointestinal submucosal tumors, laparoscopic surgery for, 161

Gastrointestinal Symptom Rating Scale, of quality of life, in gastroesophageal reflux disease, 456–458, 461

Gastroparesis, 975–985
complications of, 979
definition of, 975
differential diagnosis of, 977, 979
etiology of, 975, 978–979
laboratory tests for, 977
management of, 980–985
anti-emetics in, 982
botulinum toxins in, 983
diet in, 980
domperidone in, 981
erythromycin in, 981
exercise in, 980
gastric electrical stimulation in, 984
gastric pacing and stimulation in, 983–985
jejunal tube feeding in, 983
metoclopramide in, 980–981
tegaserod in, 981–982
total parenteral nutrition in, 983
pathophysiology of, 975–976
physical examination for, 977
symptoms of, 977

Gastroplasty
in laparoscopic repair, of paraesophageal hernias, 112

Gastroplasty, Collis
for paraesophageal hernias, 427–428
for short esophagus, 439, 441, 444, 940

Gatekeeper system, for gastroesophageal reflux disease. *See* Endoscopic surgery.

General anesthesia, indications for, 1078–1080

Genitourinary dysfunction, laparoscopic rectal surgery and, 68–69

Genitourinary toxicity, of chemotherapy, 1270

Ghrelin, in bariatric surgery, 734

Glucagon-like peptide-1, in bariatric surgery, 734–735

Glucocorticoids, for adrenal insufficiency, in septic shock, 1159

Gout, obesity and, 686–687

Graduated compression stockings, to prevent venous thromboembolism, 1170

Growth hormones, in critical illness, 1159

Gut decontamination, to prevent health care–associated pneumonia, 1139

H

Hand-assisted laparoscopic surgery
for colon cancer, 50
for Crohn's disease, 29–30
for ulcerative colitis, 44–45

Hand hygiene, to prevent health care–associated infections, 1146

Health care–associated infections, **1137–1152**
intravascular catheter–related, 1144–1146
diagnosis of, 1145
epidemiology of, 1144
management of, 1145
prevention of, 1145–1146
risk factors for, 1145
pneumonia, 1137–1142
diagnosis of, 1138
epidemiology of, 1137–1138
management of, 1138
prevention of, 1139–1142
factors related to endotracheal intubation, 1139
factors related to mechanical ventilation, 1139
pharmacologic, 1139
risk factors for, 1138
prevention of, hand hygiene in, 1146
urinary tract, 1142–1144
diagnosis of, 1143
epidemiology of, 1142–1143
management of, 1143
prevention of, 1143–1144
risk factors for, 1144

Health-care power of attorney, in surgical palliative care, 277
legal issues in, 293

Heart block, postoperative, 1107

Heart rate, in postoperative arrhythmias, 1105–1106

Heart valves, mechanical, and risk of venous thromboembolism, 1185–1187

Helicobacter pylori
and acid-peptic disorders. *See* Acid-peptic disorders.
and gastric lymphoma, 1013

Heller myotomy, for achalasia, 489
laparoscopic, 490–491

Hemophilia, and postoperative hemorrhage, 1210–1211

Hemorrhage, postoperative. *See* Postoperative hemorrhage.

Hemorrhagic cystitis, chemotherapy and, 1270

Heparin
and postoperative hemorrhage, 1203–1305
effects of, on coagulation system, 1183–1185
to prevent venous thromboembolism, 1167–1173

Heparin-induced thrombocytopenia, and postoperative hemorrhage, 1204

Hepatic disease, and diffuse intravascular coagulation, 1207

Hepatic evaluation, preoperative. *See* Preoperative evaluation.

Hepatotoxicity, of chemotherapy, 1269

Hernias
gastric, laparoscopic adjustable gastric band surgery and, 132
incisional. *See* Incisional hernias.
paraesophageal. *See* Paraesophageal hernias.
port-site, laparoscopic rectal surgery and, 65

Herniorrhaphy, laparoscopic, immunology in, 4

Hiatal hernias. *See* Paraesophageal hernias.

Highly selective vagotomy, for ulcer disease, 914, 925

Hill, contributions of, to antireflux surgery, 932–933

Histamine-2 receptor antagonists, for acid-peptic disorders, 899–900
due to nonsteroidal anti-inflammatory drugs, 904

HIV-infected patients, perioperative care in, antiretroviral therapy and, 1273–1274
hypersensitivity in, 1273–1274
lipodystrophy in, 1273
liver dysfunction in, 1274
mitochondrial toxicity of, 1273

HLA-DR expression, in immunology, 7–9

Hormones
growth, in critical illness, 1159
thyroid, in critical illness, 1159

Hydrocodone, in perioperative pain management, 1249

Hyperglycemia
and surgical site infections, 1128–1129
in previously nondiabetic people, 1156–1157

Hypersensitivity, to antiretroviral therapy, 1273–1274

Hypersensitivity response, delayed-type, in immunology, 7–10

Hypertension, improvement in, Roux-en-Y gastric bypass and, 846

Hypothermia
effects of, on coagulation system, 1199, 1202–1203
intraoperative, and surgical site infections, 1126

I

Imatinib mesylate, for gastrointestinal stromal tumors, 1016–1017

Immunocompromised patients, perioperative care in. *See* Cancer patients; HIV-positive patients; Organ transplantation.

Immunology, in laparoscopic surgery, **1–18**
acute-phase proteins in, 3–4
C-reactive protein in, 3
cell-mediated immunity in, 4–7
cholecystectomy, 5–7
colorectal surgery, 3–6
cytokines in, 3–6
delayed-type hypersensitivity response and T cell-specific function in, 7–10
herniorrhaphy, 4
HLA-DR expression in, 7–9
insulinlike growth-factor binding protein 3 in, 12
interleukins in, 3–6
monocytes and macrophages in, 6–7
natural killer cells in, 6
peritoneal macrophage function in, 10–11
postoperative immunosuppression in, 1–2

postoperative tumor growth in, 2
systemic inflammatory response in, 2–4
tumor growth-stimulatory/growth-regulatory factors in, 12
tumor necrosis factor in, 5–6
tumor resistance in, 11–12

Incisional hernias
bariatric surgery and, 861
etiology of, 91
laparoscopic repair of, **91–103**
and mesh infections, 95–96
and persistent pain, 97–98
and seroma formation, 96–97
morbid obesity and, 98–99
previous failed repairs and, 99
versus open procedures, 99–101
recurrent
etiology of, 92–94
repair technique and, 92–94

Infections
health care–associated. *See* Health care–associated infections.
in laparoscopic repair, of incisional hernias, 95–96
in organ transplantation, 1280–1281
surgical site. *See* Surgical site infections.

Innervation, of stomach, 882

Inosine monophosphate dehydrogenase inhibitors, in organ transplantation, 1279–1280

Insulin resistance, calcineurin inhibitors and, 1278

Insulinlike growth-factor binding protein 3, in immunology, 12

Interferons, neoadjuvant, for gastric cancer, 1043

Interleukins, in immunology, 3–6

International Normalized Ratio
in postoperative hemorrhage, 1212
increased, management of, 1205

Intragastric mucosal resection, laparoscopic, for gastric tumors, 154–156

Intraperitoneal chemotherapy, adjuvant, for gastric cancer, 1038–1039

Intravascular catheter–related infections. *See* Health care–associated infections.

Irritant contact dermatitis, versus latex allergy, 1331–1332

Isoflurane, in general anesthesia, 1079

Ivor Lewis esophagogastrectomy, for esophageal cancer, **583–592**
clinical experience with, 590–592
historical aspects of, 583
postoperative care for, 589–590
quality of life after, 592
technique for, 584–589
assessment of local resectability, 584–585
chest wound closure, 589
gastric tube and esophagogastric anastomosis, 588–589
mobilization of esophagus, 587
mobilization of stomach, 585
right thoracotomy, 585, 587
setup and incision, 584

J

Jaundice, obstructive, palliative care for. *See* Pancreatic/biliary cancer.

Jejunal interpositions, in esophageal reconstruction, 512–514

Jejunal tube feeding, for gastroparesis, 983

Jejunoileal bypass, complications of, 864–865

Jejunostomy, feeding, for Boerhaave's syndrome, 521–522

K

Kerlix antimicrobial dressings, to prevent surgical site infections, 1130

Ketamine
for neuropathic pain, in surgical patients, 233–234
in perioperative pain management, 1250

Kidney stones, jejunoileal bypass and, 864

Knees, arthritis of, obesity and, 687

L

Lansoprazole, for acid-peptic disorders, 900–901, 903, 904

Lap-Band. *See* Laparoscopic adjustable gastric banding.

Laparoscopic adjustable gastric banding, **773–787, 789–805,** 847–849. *See also* Bariatric surgery.
adjustable silicone gastric band in, 780
American studies on, 778–782, 785
and improvement in comorbidities, 775, 776, 801–802, 848–849

Laparoscopic (*continued*)
complications of, 774, 775, 777–778, 779, 780, 781, 782, 847–848, 865
late, 795–797
perioperative, 794–795
conversion of, to open gastric bypass, 779
European studies on, 774–778, 784
for refractory morbid obesity. *See* Refractory morbid obesity.
historical aspects of, 790–791
in adolescents, 800
in massively obese patients, 799
in older patients, 799–800
in patients with body mass index of 30-35, 800–801
postoperative care for, 793–794
results of, 794–797
Swedish adjustable gastric band in, 776
techniques for, 791–793, 847
pars flaccida technique, 792–793
versus Roux-en-Y gastric bypass, 775, 781–782, 795
weight loss after, 797–799, 848
cultural differences in, 798

Laparoscopic fundoplication, for gastroesophageal reflux disease, 935–938
versus Bard EndoCinch procedure, 953

Laparoscopic Roux-en-Y gastric bypass
complications of, 865–866
versus open procedure, 844–845

Laparoscopic surgery. *See also* Minimally invasive esophagectomy.
and surgical site infections, 1118
for achalasia, 488–491
for colon cancer. *See* Colon cancer.
for Crohn's disease. *See* Crohn's disease.
for diverticular disease. *See* Diverticular disease.
for esophageal strictures, 447
for gastric tumors. *See* Gastric tumors.
for gastroesophageal reflux disease
quality of life after, 458–460
versus Stretta system, 473–474
for incisional hernias. *See* Incisional hernias.
for paraesophageal hernias. *See* Paraesophageal hernias.
for rectal cancer. *See* Rectal cancer.
for short esophagus, 439, 441
for ulcerative colitis. *See* Ulcerative colitis.
immunology in. *See* Immunology.
on spleen. *See* Spleen.
to stage esophageal cancer, 563, 564
venous thromboembolism after, prevention of, 1170–1171

Laparoscopic transhiatal esophagectomy, versus open surgery, 598–599

Laparoscopic ultrasonography, to stage esophageal cancer, 563

Laryngeal mask airways, in anesthesia, 1082–1083

Latex allergy, **1329–1340**
cost issues in, 1337–1338
definitions in, 1338–1339
evidence-based information on, 1334
historical aspects of, 1329–1330
incidence of, 1331
latex properties and, 1330–1331
patient questionnaire on, 1335
preoperative screening for, 1334–1335
prevention of, 1334
latex-safe operating room in, 1335–1337
NIOSH guidelines for, 1336
types of reactions in, 1332
versus allergic reactions, 1331–1333

Lauren classification, for gastric cancer, 1021–1022

Legal issues, in surgical palliative care, **287–302**
advance directives, 276–277, 292–293
chronic pain management, 290–292
health-care power of attorney, 277, 293
palliative analgesia and sedation, 287–290
principle of double effect, 281, 282, 288
patient autonomy, 275–277, 292
prescribing pain medications, 296–301
assessing risk of abuse, addiction, and diversion, 297–299
DEA investigation and prosecution of physician, 299–301
documentation of, 296–297
surgeon-patient communication, 294–296

Leiomyomas, laparoscopic surgery for, 161

Leiomyosarcomas, laparoscopic surgery for, 161

Leucovorin, neoadjuvant, for gastric cancer, 1043, 1045

Leukemia, acute promyelocytic, diffuse intravascular coagulation and, 1207

Leukopenia, chemotherapy and, 1271–1272

Lipodystrophy, antiretroviral therapy and, 1273

Liver dysfunction, antiretroviral therapy and, 1274

Liver failure, duodenal switch procedure and, 830

Living wills, in surgical palliative care, 276–277
legal issues in, 292–293

Lobectomy, video-assisted thoracoscopic, for esophageal cancer, 635–637

Local anesthesia
for neuropathic pain, in surgical patients, 233
in perioperative pain management, 1250–1251

Lomustine, neoadjuvant, for gastric cancer, with radiation therapy, 1046–1047

Long-limb Roux-en-Y gastric bypass, **807–817**. *See also* Bariatric surgery.
CPT codes for, 812, 813, 814
definition of, 808–812
distal approach to, 810–812, 815
insurance coverage for, 812–814
revisional, 815–816
versus short-limb, 808–812
very (very) long limbs and biliopancreatic diversion in, 814–815

Low calorie diet, for obesity, 705

Low carbohydrate diet, for obesity, 706–707

Low-dose unfractionated heparin
and postoperative hemorrhage, 1203–1305
to prevent venous thromboembolism, 1167–1173

Low-molecular-weight heparin, to prevent venous thromboembolism, 1167–1173

Lung cancer, brain metastases from, management of, 338–339

Lymph node dissection
for esophageal cancer, 622
for gastric cancer, 1025–1029

Lymphatic system, of stomach, 882–883

Lymphomas, gastric non-Hodgkin's
Helicobacter pylori and, 1013
limited resection of, 1012–1014

M

Macrophages, in immunology, 6–7, 10–11

Magnetic resonance imaging, in staging, of esophageal cancer, 560–561

Malabsorptive procedures, for obesity. *See* Biliopancreatic diversion.

Malabsorptive/restrictive procedures, for obesity. *See* Roux-en-Y gastric bypass.

Malnutrition, biliopancreatic diversion and, 837–838

Manometry
antroduodenal, to assess gastric function, 971
esophageal, before antireflux surgery, 939
of achalasia, 484
of epiphrenic diverticula, 500
of short esophagus, 436

Massively obese patients, laparoscopic adjustable gastric banding in, 799

Mastectomy, neuropathic pain after, 228

MeCCNU, adjuvant, for gastric cancer, 1037

Mechanical heart valves, and risk of venous thromboembolism, 1185–1187

Mechanical ventilation, and pneumonia. *See* Health care–associated infections, pneumonia.

Mediastinal dissection, in transhiatal esophagectomy, 596–597

Medical Outcomes Study Short Form, of quality of life
after esophagectomy, 650, 654–655
in gastroesophageal reflux disease, 455–461

Medicare coverage, of bariatric surgery, 669–670

Melanoma, brain metastases from, management of, 339–340

Meperidine, in perioperative pain management, 1249

Mesenteric division, in laparoscopic surgery, for Crohn's disease, 30

Mesh infections, in laparoscopic repair, of incisional hernias, 95–96

Mesh repair, of hiatal hernias, 940–941

Metabolic complications, of calcineurin inhibitors, 1278

Metabolic syndrome
improvement in, Roux-en-Y gastric bypass and, 845
obesity and, in children and adolescents, 685

Metastatic disease
of brain, palliative care for. *See* Brain metastases.
skeletal, palliative care for. *See* Orthopedic surgery.

Metformin, for obesity, 711

Methadone, for neuropathic pain, in surgical patients, 230–231

Methemoglobinemia, local anesthesia and, 1251

Methotrexate, neoadjuvant, for gastric cancer, 1043
with radiation therapy, 1046–1047

N-Methyl-D-aspartate receptor antagonists, for neuropathic pain, in surgical patients, 233–234

Methyl-lomustine, adjuvant, for gastric cancer, 1037

Methylphenidate, for brain metastases, 331

Metoclopramide, for gastroparesis, 980–981

Mexiletine, for neuropathic pain, in surgical patients, 233

Minilaparotomy, for ulcerative colitis, 44–45

Minimally invasive esophagectomy, for esophageal cancer, **631–647**
complications of, 643
results of, 643–645
contraindications to, 634–635
endoscopic, 633
indications for, 634
oncologic perspectives on, 645
patient selection for, 634
postoperative care for, 642–643
preoperative evaluation for, 634
results of, 643–645
technique for, 635–642
anastomosis, 640–642
anesthesia, 635
esophageal mobilization, 635–637
gastric mobilization and preparation of gastric conduit, 637–640
laparoscopy, 637–640
neck dissection, 640–642
video-assisted thoracoscopic lobectomy, 635–637

Minnesota Multiphasic Personality Inventory, of quality of life, before and after bariatric surgery, 747

Misoprostol, for acid-peptic disorders, 902

Mitochondrial toxicity, of antiretroviral therapy, 1273

Mitomycin
adjuvant, for gastric cancer, 1037, 1038, 1039
with radiation therapy, 1040
neoadjuvant, for gastric cancer, 1043

Moderate protein/moderate carbohydrate diet, for obesity, 707

Monitored anesthesia care, indications for, 1077–1078

Monocytes, in immunology, 6–7

Monomorphic ventricular tachycardias, postoperative, 1112

Morbid obesity
and laparoscopic repair, of incisional hernias, 98–99
bariatric surgery for. *See* Bariatric surgery.
refractory. *See* Refractory morbid obesity.

Morphine
for dyspnea, in advanced cancer, 241–242
in perioperative pain management, 1248–1249

Mucosa associated lymphoid tissue, management of, 1013

Multifocal atrial tachycardias, postoperative, 1107–1108

Musculoskeletal disorders, obesity and, 686–687

Mycophenolate mofetil, in organ transplantation, 1279–1280

Mycophenolic acid, in organ transplantation, 1279–1280

Myelosuppression, chemotherapy and, 1271

Myocardial infarction, obesity and, 686

Myocardial ischemia, perioperative, protection against. *See* Perioperative beta-blockade.

Myoelectrical activity, in gastric motility, 972–973, 975

Myotomy, with diverticulectomy, for pharyngoesophageal diverticula, 496, 498

N

Narcotics, and postoperative nausea and vomiting, 1233

Natural killer cells, in immunology, 6

Nausea and vomiting
chemotherapy and, 1270–1271
in advanced cancer. *See* Advanced cancer.
postoperative. *See* Postoperative nausea and vomiting.

NDO Plicator, for gastroesophageal reflux disease. *See* Endoscopic surgery.

Nd:YAG laser therapy, for esophageal cancer, 572

Neck dissection, neuropathic pain after, 228

Nerve blocks
and postoperative nausea and vomiting, 1233
for cancer-related pain, 366–367

Neuroendocrine regulation, of gastric acid secretion, 884–886

Neuropathic pain, in surgical patients. *See* Chronic pain management.

Neurotoxicity
of calcineurin inhibitors, 1278
of chemotherapy, 1270–1271

Neutropenia, chemotherapy and, 1272

Night-eating syndrome, and patient selection, for bariatric surgery, 744

Nissen, contributions of, to antireflux surgery, 931, 933–934

Nissen fundoplication
for gastroesophageal reflux disease, 400–402
quality of life after, 460
for paraesophageal hernias, 424
in laparoscopic repair, of paraesophageal hernias, 115

Nizatidine, for acid-peptic disorders, 899–900

Non-Hodgkin's lymphomas, gastric
Helicobacter pylori and, 1013
limited resection of, 1012–1014

Nonopioid analgesia, in perioperative pain management. *See* Perioperative pain management.

Nonsteroidal anti-inflammatory drugs
and acid-peptic disorders. *See* Acid-peptic disorders.
for chronic pain, in surgical patients, 217–219
in balanced perioperative analgesia, 1253
in perioperative pain management, 1246–1248

NoThing left behind program. *See* Patient safety practices.

Nuclear medicine studies, of paraesophageal hernias, 420

Numeric rating scale, in pain assessment, 1251–1252

Nutritional deficiencies, bariatric surgery and, 713, 715–716, 860

Nutritional factors
in perioperative care, of elderly, 1262
in surgical site infections, 1128–1129

O

Obese patients. *See also* Obesity.
perioperative care in, **1283–1289**
airway management in, 1286
body mass index in, 1283
cardiac disease and, 1284
diabetes mellitus and, 1285
in bariatric surgery, 1285
obstructive sleep apnea and, 1284
operating room set-up and, 1285–1286
pain management in, 1287
preoperative assessment and, 1283–1285
pulmonary complications and, 1286–1287
surgical site infections and, 1285
venous thromboembolism and, 1284–1285

Obesity. *See also* Obese patients.
bariatric surgery for. *See* Bariatric surgery.
health ramifications of, **681–701**
breast cancer, 687–689

Obesity (*continued*)
cardiovascular disease, 685–686
colon cancer, 692
diabetes mellitus, 684–685
in children and adolescents, 685
economic costs of, 694–695
in children and adolescents, 683, 685
metabolic syndrome, in children and adolescents, 685
mortality, 684
musculoskeletal disorders, 686–687
ovarian cancer, 690–691
pancreatic cancer, 692–693
prostate cancer, 689
public health issues, 683
pulmonary disorders, 693–694
renal cell carcinoma, 691–692
uterine cancer, 690
management of, **703–723**
behavioral approaches to, 717, 718
counseling in, to improve outcome, 716–717
dietary, 704–706
after bariatric surgery. *See* Bariatric surgery.
before bariatric surgery, 711–713
calcium in, 707
composition of, 706–707
low calorie diet in, 705
low carbohydrate diet in, 706–707
moderate protein/moderate carbohydrate diet in, 707
very low calorie diet in, 705–706
increased energy output in, 707–709
limit-setting skills in, 717, 718–719
motivational interviewing in, 717, 718
pharmacologic, 710–711
bupropion in, 711
metformin in, 711
Orlistat in, 710
Sibutramine in, 711
topiramate in, 711
psychologic factors in, 712
self-nurturing in, 717, 718–719
morbid
and laparoscopic repair, of incisional hernias, 98–99
bariatric surgery for. *See* Bariatric surgery.
refractory. *See* Refractory morbid obesity.
prevalence of, 681–683

Obesity hyperventilation syndrome, clinical features of, 693

Obstructive jaundice, palliative care for. *See* Pancreatic/biliary cancer.

Obstructive sleep apnea
in obese patients, 694
and perioperative care, 1284

Omental pouch, for ulcer disease, 915

Omeprazole, for acid-peptic disorders, 900–901, 903, 904

Operating room management, **1291–1297**
air handling in, 1294–1295
maintenance in, 1295
repairs and renovations in, 1296
room requirements in, 1292–1293
room turnover in, 1295–1296
sterile processing in, 1294
storage considerations in, 1293–1294
traffic patterns in, 1291–1292

Opiates
in balanced perioperative analgesia, 1253
in perioperative pain management, 1248–1249

Opioids
and postoperative nausea and vomiting, 1233
for chronic pain, in surgical patients, 220–221
in surgical intensive care unit, 310
legal issues in. *See* Legal issues.
for dyspnea, in advanced cancer, 241–242
for neuropathic pain, in surgical patients, 229–231
in balanced perioperative analgesia, 1253
in perioperative pain management. *See* Perioperative pain management.

Organ transplantation
palliative care in, **373–382**
appropriate measures consistent with patient choice in, 376
model for, 378–379
pain management in, 376–377
recognition of physician's right to forego futile treatment in, 380

recognition of psychologic, social, and spiritual issues in, 377–378
respect for dignity of patients and caregivers in, 374–375
respect for patient's and family's wishes in, 375–376
respect for patient's right to refuse treatment in, 379–380
perioperative care in, 1274–1281
antimetabolites in, 1279–1280
biologic agents in, 1280
calcineurin inhibitors in, 1276–1278
cortisol production in, 1276
infections and, 1280–1281
sirolimus in, 1278–1279
steroids in, 1275–1276
wound healing in, 1275–1276, 1279

Orlistat, for obesity, 710

Orthopedic surgery, palliative care in, **347–357**
decision-making process in, 348
for impending pathologic fractures, 349–352
future directions in, 353–356
cementoplasty, 353
radiofrequency thermal ablation, 353–355
goals of treatment, 348–349

Osteoarthritis, obesity and, 686–687

Ovarian cancer, obesity and, 690–691

Oxcarbazepine, for neuropathic pain, in surgical patients, 232

Oxycodone, in perioperative pain management, 1249

Oxygen, for dyspnea, in advanced cancer, 242

Oxygenation, postoperative, and surgical site infections, 1129

P

Pacemaker region/activity, in gastric motility, 972

Pain management
chronic. *See* Chronic pain management.
perioperative. *See* Perioperative pain management.
postoperative, pulmonary factors in, 1070

Pancreatic/biliary cancer
obesity and, 692–693
palliative care for, **359–371**
cancer-related pain, 366–367
duodenal obstruction, 365–366
endoscopic palliation, 366
surgical palliation, 365–366
obstructive jaundice, 361–364
endoscopic and percutaneous palliation, 361–363
surgical palliation, 363–364
pancreaticoduodenectomy in, 368
unresectable periampullary cancer, 359–360

Pancreatic pseudocysts, transgastric drainage of, 1000–1005

Pancreaticoduodenectomy, for pancreatic/biliary cancer, 368

Pantoprazole, for acid-peptic disorders, 900–901, 903, 904

Paraesophageal hernias, **411–432**
as contraindication, to laparoscopic adjustable gastric banding, 802
classification of, 105–106
clinical features of, 416–418
etiology of, 107–108
evaluation of, 418–421
barium contrast studies in, 419, 426–427
endoscopic, 419–420
esophageal function tests in, 420
nuclear medicine studies in, 420
laparoscopic repair of, **105–118,** 425
outcomes of, 108
quality of life after, 110
techniques for, 110–115
Collis gastroplasty, 112
fundoplication, 115
hernia sac excision, 112–113
mobilization, 111–112
reapproximation of hiatus, 113
short esophagus, 110–111
subdiaphragmatic anchoring of stomach, 113, 115
versus open procedures, 108, 425
management of, 421–429
Collis gastroplasty in, 427–428
esophageal lengthening in, 426–428
fundoplication in, 423–424
observation versus elective repair versus urgent repair in, 428–429

Paraesophageal hernias (*continued*)
prosthetic patch repair in, 426
transabdominal versus transthoracic repair in, 421–423
mesh repair of, 940–941
parahiatal hernias, 415–416
recurrent, after laparoscopic surgery, 425
sliding, clinical features of, 411–413
symptoms of gastroesophageal reflux disease with, 416–417, 423
type I: sliding hiatal hernias, 411–412
type II: paraesophageal hernias, 413–414
type III: combined sliding and paraesophageal hiatal hernias, 414–415
type IV: complex paraesophageal hiatal hernias, 415

Parahiatal hernias, clinical features of, 415–416

Partial fundoplication, for gastroesophageal reflux disease, 935

Partial gastrectomy, for ulcer disease, 917, 919, 921–924

Patient safety practices, in operating room, **1307–1319**
correct-site surgery, 1308–1311
communication in, 1309
final "time-out" in, 1311
JCAHO sentinel event database on, 1308
type of surgery and, 1308–1309
universal protocol for, 1309–1311
NoThing left behind, 1311–1317
ACS statement on, 1313–1314
detection of retained objects in, 1315
manual counting in, 1314–1315
methodical operative site exploration in, 1316–1317
optimal operating room environment in, 1315

Peptide YY, in bariatric surgery, 734–735

Periampullary cancer, palliative care for, 359–360

Pericardial effusions, palliative surgery for. *See* Thoracic surgery.

Pericardial-pleural window, for pericardial effusions, 325

Pericardiocentesis, for pericardial effusions, 324–325

Perioperative anemia, **1215–1227**
and operative mortality, 1217–1218
diagnosis of, 1220
epidemiology of, 1216–1217
management of, 1221–1224
blood transfusions in, 1223–1224
recombinant human erythopoietin in, 1221–1223
pathophysiology of, 1218–1219
prevalence of, 1216
prevention of, 1224–1225

Perioperative beta-blockade, **1091–1102**
cardiac complications and, 1093
cardiac ischemia pathophysiology and, 1094
cardiovascular risk assessment and, 1091
choice of drugs for, 1098
clinical studies of, 1095–1097
effects of, 1094
patient selection for, 1097
timing and duration of, 1098–1099

Perioperative care
clinical pathways in, **1321–1327**
American Heart Association review of, 1322
barriers to, 1324
benefits of, 1324
common features of, 1322–1323
fast-tracking in, 1325
goals of, 1322
potential problems with, 1324
type of surgery and, 1323, 1325
in cancer patients. *See* Cancer patients.
in elderly, **1259–1266**
anesthesia and, 1262–1263
cardiovascular physiology and, 1260
end-of-life issues and, 1264
nutrition and, 1262
pain management in, 1263
postoperative delirium and cognitive dysfunction and, 1263–1264
preoperative assessment and, 1259–1260
pulmonary physiology and, 1261
quality-of-life issues and, 1264
renal physiology and, 1261–1262
in HIV-positive patients. *See* HIV-positive patients.
in obese patients. *See* Obese patients.
in organ transplantation. *See* Organ transplantation.
risk-adjusted outcomes in, **1341–1346**
ACS National Surgery Quality Improvement Program in, 1345–1346

administrative databases in, 1345
National Surgery Quality Improvement Program in, 1341–1345

Perioperative pain management, **1243–1257**
balanced perioperative analgesia in, 1252–1254
continuous epidural catheters in, 1252–1253
continuous regional anesthetic infusions in, 1253–1254
in postoperative period, 1253
nonsteroidal anti-inflammatory drugs in, 1253
opiates in, 1253
opioids in, 1253
pain assessment in, 1253
preemptive medication in, 1252
preoperative interview in, 1252
descending pain modulation and, 1245
in elderly, 1263
in obese patients, 1287
inflammatory process and, 1244–1245
local anesthesia in
and methemoglobinemia, 1251
cardiac effects of, 1250
central nervous system effects of, 1250–1251
pharmacology of, 1250–1251
nerve anatomy and, 1245–1246
nonopioid analgesia in, 217–220
pharmacology of, 1246–1248
acetaminophen, 1246
COX-2 inhibitors, 1247
nonsteroidal anti-inflammatory drugs, 1246–1248
opioid analgesia in, pharmacology of, 1248–1250
codeine, 1249
fentanyl, 1249
hydrocodone, 1249
ketamine, 1250
meperidine, 1249
morphine, 1248–1249
opiates, 1248–1249
opioids, 1248–1249
oxycodone, 1249
tramadol, 1249
pain assessment in, 1251–1252

Peritoneal macrophages, in immunology, 10–11

Peterson's defect, laparoscopic gastric bypass and, 866

pH monitoring, of achalasia, 485

pH tests, before antireflux surgery, 939

Phantom limb pain, after amputation, 228

Pharyngoesophageal diverticula. *See* Esophageal diverticula.

Photodynamic therapy, for esophageal cancer. *See* Esophageal cancer.

Photofrin, in photodynamic therapy, for esophageal cancer, 572

Physician-assisted suicide, in surgical palliative care, 281–285

Pirenzepine, for acid-peptic disorders, 898–899

Pituitary-adrenal axis, in critical illness, 1157–1159

Pituitary-gonadal axis, in critical illness, 1159–1160

Plain films, of pleural effusions, 318

Platelet inhibitors, effects of, on coagulation system, 1203

Pleural effusions
palliative surgery for. *See* Thoracic surgery.
sympathetic, transhiatal esophagectomy and, 603

Pleurodesis, for pleural effusions, 322–323

Plication/sewing techniques, for gastroesophageal reflux disease, 950–955

Pneumonia, ventilator-associated. *See* Health care–associated infections, pneumonia.

Polymethylmethacrylates, for gastroesophageal reflux disease. *See* Endoscopic surgery.

Polymorphic ventricular tachycardias, postoperative, 1112

Portal vein injury, bariatric surgery and, 863–864

Port-site hernias, laparoscopic rectal surgery and, 65

Port-site metastases, laparoscopic rectal surgery and, 66

Postemetic rupture of esophagus. *See* Boerhaave's syndrome.

Posterior vagotomy, for ulcer disease, 926

Postoperative arrhythmias, **1103–1114**
bradycardias, 1106–1112

atrial fibrillation and flutter, 1108–1111
heart block, 1107
sinus node dysfunction, 1106–1107
supraventricular tachycardias, 1107–1108
ventricular tachycardias, 1111–1112
classification of, 1104
diagnosis of, 1104–1106
heart rate in, 1105–1106
P wave and QRS relationship in, 1105
P wave location in, 1105
QRS morphology in, 1105
factors predisposing to, 1106

Postoperative hemorrhage, **1191–1213**
blood transfusions and, 1209–1210
diagnosis of, 1197–1199
assessment of coagulopathy in, 1198–1199
coagulation tests in, 1198–1199
complete blood count in, 1198–1199
hypothermia in, 1199, 1202–1203
versus screening, 1198
diffuse intravascular coagulation and, 1206–1208
and acute promyelocytic leukemia, 1207
blood products and, 1207
hepatic disease and, 1207
management of, 1208
hemophilia and, 1210–1211
International Normalized Ratio in, 1205, 1212
management of, 1199, 1202–1206
anticoagulants in, 1203–1205
fresh-frozen plasma, 1204–1205
heparin, 1203–1205
warfarin, 1205
aspirin in, 1203
platelet inhibitors in, 1203
thrombolytic agents in, 1206
preoperative screening for, 1192–1197
abnormal test results in, 1192–1193
bleeding time in, 1194–1195
coagulation tests in, 1194
complete blood count in, 1194
cost-benefit analysis in, 1196–1197
history and physical examination in, 1193–1194
in high-risk surgical patients, 1196
routine, 1192
versus diagnosis, 1198
prostate surgery and, 1209
prothrombin time in, 1212
renal dysfunction and uremia and, 1208
transhiatal esophagectomy and, 601, 604
uterine bleeding and, 1209

Postoperative nausea and vomiting, **1229–1241**
anatomy in, 1229–1230
in children, 1231–1232
literature review on, 1230–1232
management of, 1233, 1236
narcotics and, 1233
nerve blocks and, 1233
opioids and, 1233
prevention of, 1236
future research on, 1237
nonpharmacologic, 1236–1237
regional anesthesia and, 1232–1233
risk factors for, 1232
type of surgery and, 1230–1231

Posttransfusion purpura syndrome, management of, 1210

Premature ventricular contractions, postoperative, 1111

Preoperative evaluation, **1061–1073**
cardiac, 1062–1067
patient history in, 1063
predictors of risk in, 1063–1066
risk factors in, reduction of, 1066–1067
for esophageal reconstruction, 507–508
for minimally invasive esophagectomy, 634
for transhiatal esophagectomy, 594–595
of obese patients, 1283–1285
pulmonary, 1067–1070
arterial blood gas measurements in, 1069
for sleep apnea, 1068
smoking history in, 1069
spirometry in, 1069
to reduce postoperative pain, 1070
renal and hepatic, 1070–1071
for uncontrolled diabetes mellitus, 1071
smoking history in, 1071

Propofol
in conscious sedation, 1078
in general anesthesia, 1079

Prostaglandin analogs, for acid-peptic disorders, 902

Prostaglandins, as protection, against acid-peptic disorders, 898

Prostate cancer
brain metastases from, management of, 339–340
obesity and, 689

Prostate surgery, and postoperative hemorrhage, 1209

Prosthetic patch repair, of hiatal hernias, 426

Protamine, to reverse effects of heparin, in anticoagulated patients, 1184

Protein malnutrition, after bariatric surgery, 715

Prothrombin time, in postoperative hemorrhage, 1212

Proton pump inhibitors, for acid-peptic disorders, 900–901, 903, 904
due to *Helicobacter pylori*, 903
due to nonsteroidal anti-inflammatory drugs, 904

Proximal gastric cancer, limited resection of, 1010–1011

Proximal gastric ulcers, surgical management of, 922–924

Proximal gastric vagotomy, for ulcer disease, 925

Pseudocysts, pancreatic, transgastric drainage of, 1000–1005

Psychiatric disorders, and patient selection, for bariatric surgery, 742–743

Psychological General Well-Being Index, of quality of life, in gastroesophageal reflux disease, 456–458, 461

Pulmonary complications, postoperative, in obese patients, 1286–1287

Pulmonary disorders
bariatric surgery and, 862–863
in elderly, and perioperative care, 1261
obesity and, 693–694

Pulmonary edema, negative pressure, pleural effusions and, 319–320

Pulmonary embolism. *See* Venous thromboembolism.

Pulmonary evaluation, preoperative. *See* Preoperative evaluation.

Pulmonary function tests
in elderly, 1261
in preoperative evaluation, 1069

Pulmonary toxicity, of chemotherapy, 1269

P waves, in postoperative arrhythmias, 1105

Pyloroplasty, for ulcer disease, 916–917

Q

QRS complex, in postoperative arrhythmias, 1105

R

Rabeprazole, for acid-peptic disorders, 900–901, 903, 904

Radiation therapy
for brain metastases. *See* Brain metastases.
for esophageal cancer. *See* Esophageal cancer.
for gastric non-Hodgkin's lymphoma, 1014
for impending pathologic fractures, 350
neoadjuvant, for gastric cancer, 1045–1046

Radical neck dissection, neuropathic pain after, 228

Radiofrequency thermal ablation
for gastroesophageal reflux disease. *See* Endoscopic surgery, Stretta procedure.
for skeletal metastatic disease, 353–355

RAND/Agency for Health Care Research and Quality review, of bariatric surgery, 676

Ranitidine, for acid-peptic disorders, 899–900

Recombinant human erythropoietin, for perioperative anemia, 1221–1223

Rectal cancer
and perioperative anemia, 1216–1217
brain metastases from management of, 339
laparoscopic surgery for, **61–73**
and anastomotic leak, 62, 64
complications of, 65–66
conversion rates in, 64
duration of, 64
feasibility of, 64

Rectal cancer (*continued*)
immunology in, 3–6
outcomes of, 64–66
functional, 68–69
port-site metastasis in, 66
recurrence after, 66–68
safety of, 62, 64
sphincter preservation in, 64
versus en-bloc resection, 61–62

Rectal surgery, venous thromboembolism after, prevention of, 1172

Recurrent laryngeal nerve injuries, transhiatal esophagectomy and, 602

Red blood cell transfusions, for perioperative anemia, 1223–1224

Refeeding syndrome, after bariatric surgery, 715–716

Reflux-Related Visual Analogue Scale, of quality of life, in gastroesophageal reflux disease, 456–457

Refractory morbid obesity
laparoscopic adjustable gastric band surgery for, **129–140**
band removal in, 136–137
comorbidity resolution in, 135–136
complications of, 131–133
conversion rates in, 130
follow-up of, 136
patient attitudes about, 134–135
safety of, 130–131
versus open procedures, 131
weight loss after, 133–134
laparoscopic biliopancreatic diversion for, **141–149**
literature review on, 142–146
recent advances in, 147–148
revisional surgery, 147
two-stage procedure, 146
laparoscopic gastric bypass for, **119–127**
complications of, 123, 125
historical aspects of, 120
outcomes of, 122–125
variations on, 121–122
versus open procedures, 120–121

Regional anesthesia
and postoperative nausea and vomiting, 1232–1233
continuous infusions of, in balanced perioperative analgesia, 1253–1254
indications for, 1075–1076

Renal cell carcinoma
brain metastases from, management of, 339
obesity and, 691–692

Renal disease
and postoperative hemorrhage, 1208
in elderly, and perioperative care, 1261–1262

Renal evaluation, preoperative. *See* Preoperative evaluation.

Renal toxicity, of calcineurin inhibitors, 1277–1278

Resting energy expenditure, in advanced cancer, 238

Restrictive procedures, for obesity. *See* Laparoscopic adjustable gastric banding; Vertical banded gastroplasty.

Reverse transcriptase-polymerase chain reaction assay, of esophageal cancer, 564–565

Rheumatoid arthritis, obesity and, 686–687

Ritalin, for brain metastases, 331

Roux-en-Y gastric bypass, 841–847. *See also* Bariatric surgery.
and improvement in comorbidities, 845–846
complications of, 841, 844–845
for refractory morbid obesity, 122–123
complications of, 131–132
follow-up of, 136
versus laparoscopic adjustable gastric band surgery, 131
inadequate weight loss after, 857–858, 860
long-limb. *See* Long-limb Roux-en-Y gastric bypass.
open, versus laparoscopic, 844–845
short-limb, versus long-limb, 808–812
techniques for, 841
versus laparoscopic adjustable gastric banding, 775, 781–782, 795
weight loss after, 845

S

Satiety, physiology of, 889

Scintigraphy, nuclear, of paraesophageal hernias, 420

Sedation
conscious
indications for, 1077–1078
terminal, in surgical palliative care, 281

legal issues in, 287–290

Seizures, from brain metastases, prevention of, 331

Selective serotonin reuptake inhibitors, for neuropathic pain, in surgical patients, 231

Selective vagotomy, for ulcer disease, 914, 925

Self-expanding endoluminal stents, for gastric cancer, 1012

Sentinel lymph node biopsy, for gastric cancer, 1023

Septic shock, adrenal insufficiency in, 1158

Seroma formation, in laparoscopic repair, of incisional hernias, 96–97

Serum uric acid concentration, elevated, obesity and, 687

Sevoflurane, in general anesthesia, 1079

Sew-Right device, for gastroesophageal reflux disease, 470–471

Sharps injuries, **1299–1305**
incidence of, 1300
prevention of
blunt suture needles in, 1302
double gloving in, 1302
neutral passing zone in, 1302–1303
suture needles and, 1300–1301

Short esophagus, 433–435
and antireflux surgery, 939–940
definition of, 433–434
epidemiology of, 434–435
intraoperative diagnosis of, 436–438
management of, 439–445
Collis gastroplasty in, 439, 441, 444
Collis-Nissen procedure in, 439, 441
esophageal lengthening in, 441, 444
laparoscopic, 439, 441
pathogenesis of, 435
preoperative diagnosis of, 435–436

Short-Form Survey, of quality of life, in obese patients, 745

Short-limb Roux-en-Y gastric bypass, versus long-limb, 808–812

Sibutramine, for obesity, 711

Sigmoid colectomy, laparoscopic, for diverticular disease. *See* Diverticular disease.

Sinus node dysfunction, postoperative, 1106–1107

Sirolimus, in organ transplantation, 1278–1279

Sleep apnea
in obese patients, 694
and perioperative care, 1284
preoperative evaluation of, 1068

Sleep eating, and patient selection, for bariatric surgery, 744

Small cell lung cancer, brain metastases from, management of, 339

Smoking history, in preoperative evaluation, 1069, 1071

Spinal cord injuries, venous thromboembolism in, prevention of, 1173

Spiritual issues, in surgical palliative care, 196–197, **257–272**
culture and, 265
definition of spirituality, 257–259
dying patients' attitudes about discussions with physicians, 260–261
for end-stage organ failure, 377–378
in home versus institutional settings, 265
looking for a "good death," 259–261
major spiritual concerns, 264
physician burnout, 267
physician's grief, 266–268
potential for healing in death, 268–270
caregiver presence makes a difference, 269
patient biography in, 269
patients need to know they are dying, 269
reconciliation in, 269
principles of spiritual care, 264
religious versus spiritual pain, 264–264
suffering, 261–263
taking a spiritual history, 263

Spirometry, in preoperative evaluation, 1069

Splanchnicectomy, chemical, for cancer-related pain, 366–367

Spleen, laparoscopic surgery on, **75–90**
historical aspects of, 75–76
indications for, 77

Spleen (*continued*)
partial resection in, 84, 87
patient and trocar positioning for, 78–79
patient selection for, 76, 83–84
postoperative care for, 82–83
preoperative preparation for, 77–78
technique for, 79–82
mobilization, 79–80
parenchymal resection, 81
sealing and tamponading transected edge and removing specimen, 81–82
vascular dissection, 80–81
versus open partial resection, 84
versus open procedures, 83

Stents
for esophageal cancer. *See* Esophageal cancer.
for obstructive jaundice, 362–363
for tracheoesophageal fistulas, 579

Steroids
for brain metastases, 393–394
for dyspnea, in advanced cancer, 242
for neuropathic pain, in surgical patients, 232
in organ transplantation, 1275–1276

Stomach
acid-peptic disorders of. *See* Acid-peptic disorders.
anatomy of, 875–883, 967–968
anatomic relationships in, 878–880
arterial blood supply in, 880–881
historical aspects of, 875–876
innervation in, 882
landmarks in, 876–878
gastroesophageal junction, 876
lymphatic drainage in, 882–883
cancer of. *See* Gastric cancer.
functional anatomy and physiology of, 884–892, 968–970
accommodation, 968–969
alkaline secretion by gastric mucosa, 886–887
antropyloric coordination, 970
emptying, 969–970
evolving areas of interest in, 891–892
gastric digestion and contribution to downstream absorption, 887–888
gastric motility. *See* Gastric motility.
gastric mucosa, 884
gastroparesis. *See* Gastroparesis.
in response to meal, 889–891
neuroendocrine regulation of acid secretion, 884–886
satiety, 889
trituration, 969
functional evaluation of, 970–972
antroduodenal manometry in, 971
electrogastrography in, 971
solid phase gastric emptying scan in, 970–971
upper endoscopy in, 970
upper gastrointestinal series in, 970
subdiaphragmatic anchoring of, for paraesophageal hernias, 113, 115

Stress hyperglycemia, in previously nondiabetic people, 1156–1157

Stretta procedure, for gastroesophageal reflux disease. *See* Endoscopic surgery.

Strictures, esophageal. *See* Esophageal strictures.

Strokes, obesity and, 686

Stromal tumors, gastrointestinal. *See* Gastrointestinal stromal tumors.

Subarachnoid blocks, indications for, 1075–1076

Subxiphoid pericardial window, for pericardial effusions, 326

Sucralfate, for acid-peptic disorders, 901

Supraventricular tachycardias, postoperative, 1107–1108

Surgical palliative care, **169–189**
and medical institutions, 176
and quality of life measurements, 178–181
and surgical institutions, 177–178
as comprehensive philosophy, 181–182
chronic pain management in. *See* Chronic pain management.
consultation for, indications for, 183
developmental tasks of dying and, 174, 175
disease- versus symptom-oriented surgery in, 192
educating surgeons on, **383–391**
challenges in, **384**
EPEC project on, **387**
Journal of American College of Surgeons and, 386
principles guiding care at end of life, 389–390

resident and medical student education in, 388–389
resources and venues for, 385–386
standards for, 384–385
Surgical Education and Self-Assessment Program on, 387–388
surgical peers in, 386
symposia on, 386–387, 390
Web sites on, 387
ethical issues in. *See* Ethical issues.
evolution of, 192–193
feasibility of, 195-196
for pancreatic/biliary cancer. *See* Pancreatic/biliary cancer.
health care resources and, 197
historical aspects of, 170–171
in abdominal and pelvic surgery, 202–203
in genitourinary surgery, 203–204
in head, eye, neck, and throat surgery, 199–200
in nervous system surgery, 205
in organ transplantation. *See* Organ transplantation.
in orthopedic surgery. *See* Orthopedic surgery.
in skeletal surgery, 204–205
in surgical intensive care unit, **303–313**
bereavement and family support in, 310–311
chronic pain management in, 309–310
predictive models in, 304
surgeon-patient communication in, 305–307
ventilator withdrawal in, 308
withholding and withdrawing life support in, 307–309
in thoracic surgery. *See* Thoracic surgery.
integration of, into surgical practice, 182–187
legal issues in. *See* Legal issues.
levels of involvement in, 184
models of suffering and, 171, 174–175
patient preparation for, **191–207**
patient selection for, 193–194
patient factors in, 194–195
philosophic background of, 170–171
psychosocial factors in, 196–197
spiritual issues in. *See* Spiritual issues.

Surgical site infections, **1115–1135**
American Society of Anesthesiology score in, 1119
bariatric surgery and, 861
blood sugar control in, 1128–1129
blood transfusions in, 1127–1128
clean versus contaminated surgery in, 1116, 1122
colon surgery in, 1122
definition of, 1115–1116
hyperglycemia in, 1128–1129
in obese patients, 1285
incision management and, 1126–1127
intraoperative hypothermia and, 1126
laparoscopic surgery in, 1118
management of, 1130–1131
microbiology of, 1120–1121
nutritional factors in, 1128–1129
operating room environment and, 1125–1126
oxygenation in, 1129
preoperative preparation and, 1121–1125
antibiotic prophylaxis in, 1121–1125
choice of drugs in, 1122–1123
duration of, 1124
for traumatic injuries, 1125
oral, 1123–1124
prolonged, 1124
timing of, 1123
topical, 1124
prevention of, active device platforms in, 1129–1131
risk factors for, 1117

Swedish adjustable gastric band, in laparoscopic adjustable gastric banding, 776

Sympathetic pleural effusions, transhiatal esophagectomy and, 603

Systemic inflammatory response, in immunology, 2–4

T

Tachycardias
supraventricular, postoperative, 1107–1108
ventricular, postoperative, 1111–1112

Tacrolimus, in organ transplantation, 1276–1278

Talc pleurodesis, for pleural effusions, 322–323

Target-controlled infusion pumps, for anesthesia, 1086

T cell-specific function, in immunology, 7–10

Tegaserod, for gastroparesis, 981–982

Terminal sedation, in surgical palliative care, 281

Thermal ablation therapy, versus expandable metal stents, for esophageal cancer, 579

Thoracentesis, of pleural effusions, 318

Thoracic surgery, palliative care in, 200–202, **315–328**
for bilateral pleural effusions, 316–317
for dyspnea, 315
for pericardial effusions, 323–326
clinical features of, 323–324
diagnosis of, 324
hemodynamic effects of, 324
pathophysiology of, 323
pericardial-pleural window for, 325
pericardiocentesis for, 324–325
subxiphoid pericardial window for, 326
with pleural effusions, 325–326
for unilateral pleural effusion, 317–323
chemical fluid analysis in, 318–319
diagnostic thoracentesis of, 318
indwelling catheters for, 320, 321–322
negative pressure pulmonary edema in, 319–320
plain films of, 318
pleurodesis for, 322–323
ventilation for, 320
video thoracoscopy of, 320–321

Thoracoscopic lobectomy, video-assisted, for esophageal cancer, 635–637

Thoracoscopy
to stage esophageal cancer, 563, 564
video, of pleural effusions, 320–321

Thoracotomy, neuropathic pain after, 228

Three factor eating questionnaire, in patient selection, for bariatric surgery, 732

Thrombocytopenia, heparin-induced, and postoperative hemorrhage, 1204

Thromboembolism, venous. *See* Venous thromboembolism.

Thrombolytic agents, for postoperative hemorrhage, 1206

Thyroid hormones, in critical illness, 1159

Ti-knot device, for gastroesophageal reflux disease, 470–471

Tissue adhesives, to prevent surgical site infections, 1130

TNM staging system
for esophageal cancer, 556–557
for gastric cancer, 1024

Topiramate, for obesity, 711

Torsade de pointes, postoperative, 1112

Total fundoplication, for gastroesophageal reflux disease, 935

Total intravenous anesthesia, indications for, 1079–1080

Total parenteral nutrition, for gastroparesis, 983

Toupet fundoplication
for achalasia, 490, 491
for gastroesophageal reflux disease, 402–404
quality of life after, 460
for paraesophageal hernias, 424

Tracheal tears, transhiatal esophagectomy and, 601

Tracheoesophageal fistulas, expandable metal stents for, 579

Traction diverticula, clinical features of, 502

Tramadol
for chronic pain, in surgical patients, 219
in perioperative pain management, 1249

Transabdominal repair, of paraesophageal hernias, 421–423

Transcutaneous electrical nerve stimulation, for neuropathic pain, in surgical patients, 234

Transesophageal echocardiography, to monitor hemodynamically unstable patients, 1087

Transgastric drainage, of pancreatic pseudocysts, 1000–1005

Transgastric resection
of early gastric cancer, 993–996
of gastrointestinal stromal tumors, 996, 998–1000

Transhiatal esophagectomy, **593–610**, 632
anesthesia in, 595
complications of, 600–603
anastomotic leak, 602, 604
chylothorax, 603
cramping, 605
diarrhea, 605

hemorrhage, 601, 604
recurrent laryngeal nerve injury, 602
sympathetic pleural effusions, 603
tracheal tears, 601
contraindications to, 594
historical aspects of, 593–594
indications for, 594
postoperative care for, 599–600
preoperative evaluation for, 594–595
results of, 603–606
functional, 605–606
survival, 606
technique for, 595–599
abdominal phase, 595–596
cervical esophagogastric anastomosis, 597–598
cervical phase, 596
laparoscopic, 598–599
mediastinal dissection, 596–597

Transplantation, organ. *See* Organ transplantation.

Transpyloric gastroduodenotomy, for bleeding duodenal ulcers, 910

Transthoracic esophagectomy, for esophageal cancer, 632

Transthoracic repair, of paraesophageal hernias, 421–423

Trauma patients
antibiotic prophylaxis in, 1125
venous thromboembolism in, prevention of, 1172–1173

Triclosan, to prevent surgical site infections, 1130

Tricyclic antidepressants, for neuropathic pain, in surgical patients, 231

Trituration, gastric, physiology of, 969

Truncal vagotomy, for ulcer disease, 914, 924–925

Tumor growth-stimulatory/growth-regulatory factors, in immunology, 12

Tumor necrosis factor, in immunology, 3–6

Tumor resistance, immunology in, 11–12

Type 2 diabetes mellitus. *See* Diabetes mellitus.

U

Ulcer disease. *See also* Acid-peptic disorders.
classification of, 908
hemorrhage in, 909–911
Helicobacter pylori and, 911
surgical management of, 915–916
transpyloric gastroduodenotomy in, 910
perforation of, 909
Helicobacter pylori and, 909
surgical management of, **907–929**
Billroth procedures in, 917, 919, 921
and bile gastritis, 921
Braun enteroenterostomy in, 921
for bleeding duodenal ulcers, 909–911
for proximal gastric ulcers, 922–924
highly selective vagotomy in, 914, 925
omental patch in, 915
partial gastrectomy and restoration of foregut continuity in, 917, 919, 921–924
posterior vagotomy in, 926
proximal gastric vagotomy in, 925
pyloroplasty in, 916–917
results of, 926–927
selective vagotomy in, 914, 925
terminology of, 914–915
truncal vagotomy in, 914, 924–925
vagal interruption in, 924
limited anterior, 926

Ulceration, bariatric surgery and, 861–862

Ulcerative colitis, laparoscopic surgery for, **35–47**
hand-assisted, 44–45
historical aspects of, 36–37
in acute disease, 43–44
minilaparotomy in, 44–45
one-stage, outcomes of, 44
retrospective case studies of, 37–39
versus laparoscopic surgery for Crohn's disease, 39–41
versus open procedures, 41–43

Ultrasonography
endoscopic, to stage esophageal cancer, 556, 561–562
laparoscopic, to stage esophageal cancer, 563

Upper endoscopy, to assess gastric function, 970

Upper gastrointestinal series, to assess gastric function, 970

Uremia, and postoperative hemorrhage, 1208

Urinary tract infections, health care–associated. *See* Health care–associated infections.

Uterine bleeding, postoperative, 1209

Uterine cancer, obesity and, 690

V

Vagal interruption, for ulcer disease, 924
limited anterior, 926

Vagal signals, in bariatric surgery, 733–734

Vagotomy, for ulcer disease. *See* Ulcer disease.

Vanguard band, in laparoscopic adjustable gastric band surgery, 137

Venous thromboembolism, **1163–1177**
bariatric surgery and, 856–858
in anticoagulated patients, 1187
in obese patients, and perioperative care, 1284–1285
laparoscopic gastric bypass and, 866
prevention of
in burn patients, 1173
in cancer patients, 1171–1172
in colorectal surgery, 1172
in general surgery, 1168–1170
in laparoscopic surgery, 1170–1171
in spinal cord injuries, 1173
in trauma patients, 1172–1173
mechanical, 1166–1167
pharmacologic, 1167–1173
antiplatelet agents in, 1167
heparin in, 1167–1173
neuraxial anesthesia/analgesia and, 1167–1168
vitamin K antagonists in, 1167
risk factors for, 1164–1165

Ventilation, for pleural effusions, 320

Ventilator-associated pneumonia. *See* Health care–associated infections, pneumonia.

Ventricular tachycardias, postoperative, 1111–1112

Vertical banded gastroplasty, 847–849
and improvement in comorbidities, 848–849
complications of, 847–848
for refractory morbid obesity, versus laparoscopic adjustable gastric band surgery, 130–131
techniques for, 847
weight loss after, 848

Very low calorie diet, for obesity, 705–706

Video-assisted thoracoscopic lobectomy, for esophageal cancer, 635–637

Video thoracoscopy, of pleural effusions, 320–321

Visual analog scale, in pain assessment, 1251

Vitamin K antagonists, to prevent venous thromboembolism, 1167

Vitamin K deficiency, and postoperative hemorrhage, 1205

Vomiting
in advanced cancer. *See* Advanced cancer.
postoperative. *See* Postoperative nausea and vomiting.

W

Warfarin, effects of, on coagulation system, 1182–1183

Wedge resection, laparoscopic, for gastric tumors, 154–156, 161

Weight loss, laparoscopic adjustable gastric band surgery and, 133–134

Wernicke-Korsakoff syndrome, after bariatric surgery, 716

Wilson-Cook endoscopic suturing device, for gastroesophageal reflux disease, 470–471

Wound healing, in organ transplantation, 1275–1276, 1279

X

Zenker's diverticula. *See* Esophageal diverticula.

Zollinger-Ellison syndrome, management of, 904–905